GNPX
- Genprex, Inc.
()
Overview
Company Summary
Genprex, Inc. is a clinical-stage gene therapy company that focuses on developing therapies for patients with cancer. The company is specifically focused on utilizing the power of its proprietary technology platform, called Oncoprex, to deliver tumor suppressor genes directly into cancer cells.
Genprex's lead drug candidate, also named Oncoprex, is being developed to combat non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancer cases. Oncoprex works by delivering the TUSC2 gene, a tumor suppressor gene, into cancer cells. This gene helps to restore normal function and growth control in cancer cells, ultimately inhibiting tumor growth and increasing susceptibility to other treatment options, such as immunotherapy or chemotherapy.
The delivery of the TUSC2 gene into cancer cells is facilitated by Genprex's proprietary nanoparticle-based delivery system. This system allows for targeted and efficient delivery of the therapeutic gene, promoting its uptake by cancer cells while minimizing effects on healthy tissues.
Genprex's focus on gene therapy differentiates it from traditional pharmaceutical companies, which typically develop small molecule drugs or biologics. Gene therapy holds significant potential for treating various types of cancers by targeting specific genetic abnormalities or mutations. Genprex aims to leverage this potential by developing innovative therapies using its Oncoprex platform.
In addition to its lead program in the NSCLC space, Genprex is exploring the application of its technology platform in other types of cancer, including breast cancer, renal cell carcinoma, and prostate cancer. The company's goal is to advance the development of effective gene therapy options to improve the outcomes of cancer patients.
Through its research and development efforts, Genprex seeks to bring new and innovative treatment options to patients, potentially revolutionizing the way cancer is treated and managed.